Last reviewed · How we verify

NCT05196997

The De-Morton Mobility Index Turkish Version in Intensive Care Patients

Completed Last updated 19 January 2022
What this trial tests

trial testing Mobility and Functional Assessments in Critical Care in 150 participants. Completed in 20 February 2019.

Timeline
1 April 2018
Primary endpoint
20 February 2019
20 February 2019

Quick facts

Lead sponsorIzmir Katip Celebi University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date1 April 2018
Primary completion20 February 2019
Estimated completion20 February 2019
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Izmir Katip Celebi University

Who can join

18 and older, any sex, with Critical Care or Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

De Morton Mobility Index is recommended for the evaluation of mobility in the evidence-based guidelines, in patients in intensive care units. The aim of our study is to examine the validity and reliability of the Turkish version of the De Morton Mobility Index in patients hospitalized in the respiratory intensive care unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Critical Care

Currently open trials in the same condition.

Other Izmir Katip Celebi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05196997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing